Citations

Clear

3030 citation(s) found for "Susan, M".

Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival
Ellingson, Benjamin M. , Wen, Patrick Y. , Chang, Susan M. , Bent, Martin J. van den , Vogelbaum, Michael A. , Li, Shanpeng , Wick, Wolfgang , Lassman, Andrew B. , Galanis, Evanthia , Wick, Wolfgang , Lassman, Andrew B , Weller, Michael , Galanis, Evanthia , van den Bent, Martin J , Ellingson, Benjamin M , Wen, Patrick Yung , Li, Gang , Kim, Jiyoon , Youssef, Gilbert , Gilbert, Mark R. , Groot, John de , Cloughesy, Timothy F.

Mayo Clinic

Neuro-Oncology | January 5, 2023 | Volume: 25 | Issue: 6 | Pages: 1017-1028

10.1093/neuonc/noad002 | PMID 36617262 Get It

Abstract Durable objective response rate (ORR) remains a meaningful endpoint in recurrent cancer; however, the target ORR for single-arm recurrent glioblastoma trials has not been based on historic information or tied to patient outcomes. The current study reviewed 68 treatment arms comprising 4793 patients in past trials in recurrent glioblastoma in order to judiciously define target ORRs for use in recurrent glioblastoma trials. ORR was estimated at 6.1% [95% CI 4.23; 8.76%] for cytotoxic chemothera + pies (ORR = 7.59% for lomustine, 7.57% for temozolomide, 0.64% for irinotecan, and 5.32% for other agents), 3.37% for biologic agents, 7.97% for (select) immunotherapies, and 26.8% for anti-angiogenic agents. ORRs were significantly correlated with median overall survival (mOS) across chemotherapy (R2= 0.4078, P < .0001), biologics (R2= 0.4003, P = .0003), and immunotherapy trials (R2= 0.8994, P < .0001), but not anti-angiogenic agents (R2= 0, P = .8937). Pooling data from chemotherapy, biologics, and immunotherapy trials, a meta-analysis indicated a strong correlation between ORR and mOS (R2= 0.3900, P < .0001; mOS [weeks] = 1.4xORR + 24.8). Assuming an ineffective cytotoxic (control) therapy has ORR = 7.6%, the average ORR for lomustine and temozolomide trials, a sample size of ≥40 patients with target ORR>25% is needed to demonstrate statistical significance compared to control with a high level of confidence (P < .01) and adequate power (>80%). Given this historic data and potential biases in patient selection, we recommend that well-controlled, single-arm phase II studies in recurrent glioblastoma should have a target ORR >25% (which translates to a median OS of approximately 15 months) and a sample size of ≥40 patients, in order to convincingly demonstrate antitumor activity. Crucially, this response needs to have sufficient durability, which was not addressed in the current study.
Multi-modal immune profiling of mucinous ovarian carcinoma: analysis from the Ovarian Tumor Tissue Analysis/Multidisciplinary Ovarian Cancer Outcomes Group consortia
Meagher, Nicola S. , Hamilton, Phineas T. , Anglesio, Michael S. , Konecny, Gottfried E. , Schildkraut, Joellen M. , Talhouk, Aline , Initiative, Australian Pancreatic Genome, Pearce, Celeste Leigh , Pike, Malcolm C. , Goode, Ellen L. , Anglesio, Michael S , Harris, Holly R. , Initiative, Australian Pancreatic Genome, Friedländer, Michael , Köbel, Martin , Doherty, Jennifer A. , Nelson, Brad H. , DeFazio, Anna , Ramus, Susan J.

Mayo Clinic

The Journal of Immunology | January 3, 2023 | Volume: 208 | Issue: Supplement_1 | Pages: 179.04-179.04

10.4049/jimmunol.208.supp.179.04 Get It

Abstract Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer. Women with advanced disease (FIGO stage III/IV) have very poor outcomes, with 5-year survival of <20%. Little is known about the anti-tumor immune response in MOC, limiting potential immunotherapeutic options for patients. Immune data from 3 platforms were analysed. A NanoString mRNA expression panel with 39 immune-related genes (n=60 MOC, n=4198 other ovarian histotypes), a NanoString mRNA plexset with PD-1, PD-L1 (n=241 MOC, n=115 upper and lower gastrointestinal (GI) cancers), and 2 multicolor immunofluorescence (mcIF) panels (n=121 MOC) for CD68, PD-L1, PD-1, CD8 and FOXP3. Data overlapped all platforms for 22 MOC. Immune marker expression by ovarian cancer histotype was measured. Uni- and multivariable Cox Proportional Hazards assessed overall survival (OS) within MOC. Hierarchical clustering looked for subgroups of patients based on co-expression of immune genes. Compared to more common high-grade serous ovarian cancer (HGSC) and GI cancers, MOC were less immunologically active. High IGHM expression was associated with poorer OS (HR 1.31 (95% CI 1.02–1.69), p=0.033). High tumor densities of FOXP3 and PD-1 positive cells conferred poorer OS in a model with age, stage and site; however, these and PD-L1 and CD68 were associated with grade. The 39 gene NanoString and mcIF datasets revealed 4 clusters, roughly translating to immune cold, moderate and hot (groups 3,4). mcIF analysis revealed a subset with PD-L1 expression in the absence of T-regulatory cell infiltrates. This study provides novel insights into the MOC immune landscape. Despite relatively low immune activity overall, immunotherapy could be explored for a subset of patients with MOC. Supported by NSW Ministry of Health and UNSW Sydney, through the NSW Health PhD Scholarship Program 2017-2022; Translational Cancer Research Network top-up scholarship 2021
Humanized PD-1/PD-L1 (HuPD) mice facilitate the direct functional comparison of immune checkpoint inhibitors in vivo
Harrington, Susan M. , Liu, Xin , Barham, Whitney , Dong, Haidong

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 195.1-195.1

10.4049/jimmunol.202.supp.195.1 Get It

Abstract Though anti-PD-1/L1 antibody therapies have generated unprecedented responses in a limited number of patients, the biological and immunological parameters that define their effective use are still largely unknown. The absence of appropriate pre-clinical models has limited our ability to compare the mechanistic differences between the approved PD-1/L1 antibodies in vivo and to determine the context in which each might be most effective. To address this critical need, we have produced humanized PD-1 and PD-L1 mice in which the extracellular domains (antibody binding sites) of mouse PD-1 and PD-L1 are replaced with the sequences of human PD-1 and PD-L1. The PD-1 and PD-L1 in the resulting “HuPD” mice can be recognized by FDA-approved antibodies, while the intracellular domains are kept intact for normal downstream signals. Following characterization of the new mouse model, in our first in vivo treatment studies, HuPD mice were immunized with OVA/Poly I:C in the context of FDA-approved PD-1/L1 antibodies and antigen-specific T cell production was quantified. Nivolumab, Pembrolizumab, and Atezolizumab all increased effector CD8+T cell production against the OVA antigen as expected given their immune stimulating function. Surprisingly, OVA-tetramer staining was unable to detect antigen-specific CD8+T cells in the spleens of immunized mice treated with Avelumab. This may reflect the unique ability of Avelumab to induce ADCC, and indicates that our model is capable of distinguishing key differences among the antibodies in vivo. Ongoing studies will identify how these differences might be exploited to render the most effective results for patients in a variety of tumor types and immune environments.
ANT2 (SLC25A5) balances the pro-apoptotic vs. effector signals of Bim in CD8 T cells
Gicobi, Joanina K. , Yu, Xiatong, Dronca, Roxana , Zhu, Mojun , Harrington, Susan M. , Vianzon, Vianca , Hirdler, Jacob, Liu, Xin, Barham, Whitney , Wen, Ti , Zhang, Henan , Vianzon, Vianca V , Hirdler, Jacob B. , Dong, Haidong

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 165.7-165.7

10.4049/jimmunol.204.supp.165.7 Get It

Abstract The immune response to anti-PD-1 therapy in cancer patients is not completely defined due to lack of reliable biomarkers that can determine T cell function. Bim, a member of the Bcl-2 family, was recently identified as a downstream signaling molecule in the PD-1 pathway. Within CD8 T cells, Bim appears to have a dual function, and can be pro-apoptotic or promote effector activity. Our clinical data has shown that high levels of Bim in CD8 T cells are predictive of response to anti-PD-1 therapy in metastatic melanoma whereas in colorectal cancer, a low level of Bim is associated with treatment response. Thus, we sought to determine what molecular partners might influence the role of Bim. Using co-immunoprecipitation, high resolution microscopy and FRET we identified ANT2 (Adenine Nucleotide Translocase 2), an inner membrane protein of mitochondria, as a protein that interacts with Bim. Accordingly, we found CD8 T cells with low and high mitochondrial potential demonstrated different ANT2/Bim ratios, and a low ANT2/Bim ratio was present in effector T cells with low mitochondrial potential but high cytotoxic activity. Given the pro-survival function of ANT2, our results indicate that ANT2 may balance the pro-apoptotic and effector roles of Bim in mitochondria in order to preserve effector T cells before contraction. Understanding the molecular mechanism of Bim and ANT2 interactions in CD8 T cells may provide a novel marker to predict clinical response to anti-PD-1 therapy.
Murine Ia Antigens: Identification and Mapping of Ia.23 and Further Definition of the I-E Subregion
David, Chella S., Cullen, Susan E.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 120 | Issue: 5 | Pages: 1659-1662

10.4049/jimmunol.120.5.1659 Get It

Abstract The Ia.23 specificity is a private specificity of the H-2d haplotype which we have assigned to the I-E subregion. It is found on the same Ia molecule that bears Ia.7, a public specificity previously assigned to the I-C subregion of haplotypes H-2d, H-2k, H-2p and H-2r. We suggest a reassignment of specificity Ia.7 to the I-E subregion to simplify the interpretation of the data presented in this paper and elsewhere, and to permit an orderly description of that part of the I region to the right of I-J.
Endogenous tumor-reactive CD8+ T cells are differentiated effector cells with high expression of CD11a and PD-1 but are unable to control tumor growth (P2089)
Gibbons, Rachel, Liu, Xin , Harrington, Susan M. , Krco, Christopher J., Markovic, Svetomir, Kwon, Eugene , Markovic, Svetomir N. , Dong, Haidong

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 190 | Issue: Supplement_1 | Pages: 170.1-170.1

10.4049/jimmunol.190.supp.170.1 Get It

Abstract We utilized CD11a, an integrin up-regulated on effector and memory CD8+ T cells, as a biomarker to identify, measure, and monitor endogenous tumor-reactive cytotoxic lymphocytes (CTLs) in two mouse tumor models and in melanoma patients. CD11ahigh CD8+ T cells were detected in primary and metastatic tumor sites after tumor cell injection, as well as in spontaneous murine breast cancer tissues. In the peripheral blood of melanoma patients, tumor antigen-specific T cells were detected within the population of CD11ahigh CD8+ T cells that express high levels of PD-1. Infusion of lethally irradiated tumor cells failed to stimulate the expansion of CD11ahigh CD8+ T cells, suggesting that the access of tumor cells to target tissues is required to induce CD11ahigh CD8+ T cell responses. Phenotypic analysis revealed that the CD11ahigh CD8+ T cells detected in our studies were proliferating (Ki67+) activated T cells (CD62L-, CD69+). Although CD11ahigh CD8+ T cells were differentiated effector cells with CTL effector functions, they were typically unable to control tumor growth in our mouse models, possibly due to high expression of PD-1. Our results demonstrate that CD11a can be used as a biomarker to identify and track endogenous tumor-reactive CTLs.
Eosinophils regulate immunity during chronic infection by Trichinella spiralis (87.14)
Bliss, Susan K., Gagliardo, Lucille F., Lee, James , Appleton, Judith A., Gebreselassie, Nebiat , Fabre, Valeria , Lee, Nancy

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 184 | Issue: Supplement_1 | Pages: 87.14-87.14

10.4049/jimmunol.184.supp.87.14 Get It

Abstract Eosinophilia is a hallmark of worm infection and allergy. The parasitic nematode Trichinella spiralis establishes chronic infection in skeletal muscle. We have shown previously that in eosinophil-ablated, transgenic mice, T. spiralis larvae die in large numbers in the muscle. Death is promoted by inducible nitric oxide synthase (iNOS). We report here that transcription of iNOS was upregulated in the context of an established alternative activation phenotype in local leukocytes. Infiltrating macrophages, dendritic cells, and neutrophils produced iNOS. These changes were preceded by a reduced T cell recruitment to infected muscle that was coincident with a lag in larval growth, suggesting compromise of the parasite’s habitat. The results further define the cellular interactions that occur at a site of chronic nematode infection in which the eosinophil functions as a pivotal regulator of immunity.
I-C Subregion Determinants on MLR Suppressor Factor
Rich, Susan Solliday, David, Chella S., Rich, Robert R.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 121 | Issue: 4 | Pages: 1622-1622

10.4049/jimmunol.121.4.1622.b Get It

Abstract MLR suppressor factor (MLR-SF) optimally suppresses MLR responses only of responder cells which are compatible in the I-C subregion with cells producing the factor. Therefore, presence of MHC-encoded determinants on MLR-SF has been investigated, with particular interest in I-C, as well as the possible role of I-J determinants. Suppressor activity of supernates of alloantigen-activated spleen cells was tested after passage over solid immunoadsorbants prepared with various anti-H-2 subregion sera. Immunoadsorbants with specificity towards K and D region products were ineffective while several preparations with I region specificity removed suppressor activity from factors of the appropriate haplotype. The single subregion specificity common to all adsorbing preparations was I-C. Recently, ambiguity has developed with regard to genetic resolution of I-C and adjacent subregions, including difficulties of serologic differentiation of I-C products of the k and d haplotypes. Antisera prepared in I-Ck/I-Cd disparate strain combinations have identified T cell restricted determinants which are distinct between these haplotypes. MLR-SF prepared from (BALB × CBA)F1 were passed over I-Cd and I-Ck specific adsorbants and residual activity tested in MLR with each parental responder cell. Exposure to anti-I-Cd removed suppressor activity for the BALB response, leaving intact suppression of CBA responses. The reciprocal situation also obtained. Furthermore, acid elution of anti-I-Cd columns exposed to F1 factor yielded material which suppressed BALB but not CBA MLR. Antisera with anti-I-Jk specificity did not remove suppressor activity of various H-2k factors. In addition, control factors passed over anti-I-Jk columns did not acquire suppressive activity, indicating that leaching of small quantities of anti-I-J antibodies had not concealed actual binding of suppressor molecules, by inducing a distinct form of suppression. Thus, I-C subregion products, restricted to T lymphocyte expression, exhibit unique association with MLR-SF suppression of MHC stimulated immune responses.
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review
Kleinstern, Geffen , Slager, Susan L.

Mayo Clinic

Leukemia & Lymphoma | December 28, 2022 | Volume: 64 | Issue: 4 | Pages: 788-798

10.1080/10428194.2022.2157215 | PMID 36576061 Get It

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
Kang, Eunyoung , Weir, Ashley , Meagher, Nicola S. , Farrington, Kyo , Nelson, Gregg , Lee, Cheng‐Han , Riggan, Marjorie J. , Popović, Gordana , Leung, Betty, Tang, Katrina , Lambie, Neil, Millstein, Joshua , Alsop, Jennifer , Anglesio, Michael S. , Barlow, Ellen , Beckmann, Matthias W. , Berger, Jessica, Bisinotto, Christiani, Bösmüller, Hans , Boros, Jessica , Brand, Alison H. , Carney, Michael E. , Casablanca, Yovanni , Cohen, Paul A. , Coulson, Penny , Courtney‐Brooks, Madeleine , Cunningham, Julie M. , Darcy, Kathleen M. , El‐Bahrawy, Mona A., Farrell, Rhonda , Fischer, Anna , García, María J. , Gayther, Simon A. , Group, AOCS, Harnett, Paul R. , Harrington, Shariska P. , Harter, Philipp , Hartmann, Arndt , Hecht, Jonathan L. , Heikaus, Sebastian, Hendley, Joy , Polo, Susanna Hernando, Heublein, Sabine , Hirasawa, Akira , Huntsman, David G. , Jimenez‐Liñan, Mercedes , Jones, Michael E. , Kennedy, Catherine J. , Khabele, Dineo , Lambrechts, Diether , Le, Nhu D. , Lener, Marcin , Lester, Jenny , Leung, Yee , Linder, Anna , Loverix, Liselore , Madan, Rashna , Maxwell, G. Larry , Olawaiye, Alexander , Oršulić, Sandra , Palacios, José , Pearce, Celeste Leigh , Pike, Malcolm C. , Quinn, Carmel M. , Mohan, Ganendra Raj , Rodríguez‐Antona, Cristina , Ruebner, Matthias , Ryan, Andy , Salfinger, Stuart , Sasamoto, Naoko , Schildkraut, Joellen M. , Schoemaker, Minouk J. , Shah, Mitul , Sharma, Raghwa , Shvetsov, Yurii B. , Singh, Naveena , Steele, Linda , Stewart, Colin J.R. , Talhouk, Aline , Tan, Adeline , Terry, Kathryn L. , Tołoczko, Aleksandra, Aa, Maaike A. van der , Gorp, Toon Van , Nieuwenhuysen, Els Van , van‐Wagensveld, Lilian, Vergote, Ignace , Wu, Anna H. , Reis, Francisco José Cândido dos , Fasching, Peter A. , Goode, Ellen L. , Goodman, Marc T. , Kommoss, Stefan , Menon, Usha , Sinn, Hans‐Peter , Staebler, Annette , Bowtell, David D.L. , Ramus, Susan J. , Lambrechts, Diether , El‐Bahrawy, Mona , Lee, Cheng-Han , Fereday, Sian , Kennedy, Catherine J , Sasamoto, Naoko , Schildkraut, Joellen M , Talhouk, Aline , Vergote, Ignace , Köbel, Martin , Lambrechts, Diether , Ramus, Susan J , Rodríguez-Antona, Cristina , Menon, Usha , Sinn, Peter , Anglesio, Michael S , Jones, Michael E , Lambrechts, Diether , Brand, Alison H , Bowtell, David D , Nelson, Gregg S , El-Bahrawy, Mona A , Harnett, Paul R , Schoemaker, Minouk J , Goodman, Marc T , Linder, Anna , Cohen, Paul , Kang, Eun‐Young, Ghatage, Prafull , Bolithon, Adelyn , Ataseven, Beyhan , Brooks‐Wilson, Angela , Brucker, Sara Yvonne , Cazorla, Alicia , Conrads, Thomas , Cook, Linda S. , Cramer, Daniel W. , Crowe, Philip John , Cybulski, Cezary , Elishaev, Esther , Erber, Ramona , Fereday, Sián , Gentry‐Maharaj, Aleksandra , Gilks, C. Blake , Group, AOCS, Grube, Marcel , Hein, Alexander , Heitz, Florian , Hernandez, Brenda Y. , Høgdall, Estrid , Høgdall, Claus , Horlings, Hugo , Huzarski, Tomasz , Jewell, Andrea , Kaufmann, Scott H. , Kommoss, Felix , Kruitwagen, Roy F.P.M. , Lubiński, Jan , Modugno, Francesmary , Neuhausen, Susan L. , Olbrecht, Siel , Sonke, Gabe S. , Sundfeldt, Karin , Swerdlow, Anthony J. , Taylor, Sarah E. , Traficante, Nadia , Van de Vijver, Koen , Vierkant, Robert A. , Wang, Chen , Wilkens, Lynne R. , Winham, Stacey J. , Benı́tez, Javier , Berchuck, Andrew , DeFazio, Anna , Gronwald, Jacek , Karlan, Beth Y. , Brenton, James D. , Pharoah, Paul D.P. , Köbel, Martin

Mayo Clinic

Cancer | December 27, 2022 | Volume: 129 | Issue: 5 | Pages: 697-713

10.1002/cncr.34582 | PMID 36572991 Get It

AbstractBackgroundCyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo‐ovarian high‐grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large‐scale, histotype‐specific validation has been performed. The hypothesis was that high‐level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC.MethodsWithin the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated.ResultsHigh‐level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% of HGSC and overexpression (>60% with at least 5% demonstrating strong intensity by immunohistochemistry) was found in 22.4%. CCNE1 high‐level amplification and overexpression both were linked to shorter overall survival in multivariate survival analysis adjusted for age and stage, with hazard stratification by study (hazard ratio [HR], 1.26; 95% CI, 1.08‐1.47, p = .034, and HR, 1.18; 95% CI, 1.05‐1.32, p = .015, respectively). This was also true for cases with combined high‐level amplification/overexpression (HR, 1.26; 95% CI, 1.09‐1.47, p = .033). CCNE1 mRNA expression was not associated with overall survival (HR, 1.00 per 1‐SD increase; 95% CI, 0.94‐1.06; p = .58). CCNE1 high‐level amplification is mutually exclusive with the presence of germline BRCA1/2 pathogenic variants and shows an inverse association to RB1 loss.ConclusionThis study provides large‐scale validation that CCNE1 high‐level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC.